Icon

CUBICIN (nda021572)- (250MG/VIAL,500MG/VIAL)

DAPTOMYCIN CUBIST PHARMS LLC
250MG/VIAL,500MG/VIAL
Yes No
2020-Nov-28 Expired
None None
None No
CUBICIN is a lipopeptide antibacterial indicated for the treatment of:  Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) and,  Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis,  Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age).
18 0 15
Total Other Developers 18
Drugs with Suitability No
250MG/VIAL ** ** - - -
500MG/VIAL ** ** - - 13
NDA Sales Available Total Generic Sales Available
No 13
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** **** *** ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** ****** ****** *** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ********* **** *** ********* **** ***, *** *********** **** *. **** ****** **** ***** ********* ******, ******* ****, ******** (**) *****, ****** ****** (***) ***
****** ** ****** ***** ****** ******* *********** ****** **. *** - ***, *** & ***, **** ************* ***** *****, *. *. *****, ******** ****, ******** - ************* ******, ******* - ********** ********, *********, ********* ******, ***** (***) ***
****** ** ****** ** *****'* ************ ******* *********** ************ ********* **********, ***-**,****** ** **,** & **** ** (**,**,**,**,**), ***** ********** ****, ************** (*), *********** (*),, **********, ****** ******* ******, ***** (***) ***
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ******* ****** ******* ******* *************** **., ***. (******* **** ****) *********** ** ******* ****, ******** & ************* *********** ****,, ***********, ******* ******, ***** (***) ***
****** ** ****** ********** *. ******* *********** **** **.*, **. **. ***/*, ******* ****, *****-**, ******* *******, ********** ******, *******, ********* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-***, **** **: *, ** ** **, ***, ** ** **, ****, *****, ***, ************ *******, ********** ******, **********, ********* ******, ***** (***) ***
****** ******** ******* ****-****** *********** ************** **.,***. (*** ****) *********** **, ** ***** ****, ******* **** *** *** ********** *********** **** ******* ******, *******, ******* ******, ***** (***) ***
****** **** ***** ****** **** ************** (******) **., ***. *********** **.***-*, ****** ******, ******** ****-**** ****, ******, ****** ******, ***** (***) ***
****** ****** **** ***** ****** **** *****. **., ***. *********** ********** ******** *********** ****, ****** ********, ******, ****** ******, ***** (***) ***
****** ****** ****** ****** ******* *********** ****** **. ***, ******* ****, ***** ***
****** ***** ***** ************ ******* *********** (***), **** **. ***-*, *********** ****** **** ****, ********** ****, ****** *****, *********, ********* ******, ***** (***) ***
****** ****** ****** ***** ************ ******* ******* *********** ******* **********, ****** **** *****, ******** ********* **** ***** *****, ****** ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.